Pregabalin (All indications) updated on 04-22-2025

Intrauterine deaths (as a whole or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18758
R79778		 Moore (Pregabalin) (Mixed indications) (Controls exposed to LTG), 2025 Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.77 [1.55;2.03] C
excluded (control group) 		849/2,337   481/1,976 1,330 2,337
ref
S18759
R79782		 Moore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 Pregnancy loss (pregnancy outcome other than live birth at any gestation, including spontaneous loss (miscarriage, stillbirth) and termination of pregnancy) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Matched 1.44 [1.30;1.58] 849/2,337   5,539/22,850 6,388 2,337
ref
Total 1 studies 1.44 [1.31;1.59] 6,388 2,337
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025Moore, 2025 1 1.44[1.30; 1.58]6,3882,3370%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Pregabalin) (Mixed indications) (Controls unexposed, general pop;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 1 Tags Adjustment   - Yes  - Yes 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 1 MatchedMatched 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 1 All studiesAll studies 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18758

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.44[1.31; 1.59]6,3882,337 -NAMoore (Pregabalin) (Mixed indications) (Controls unexposed, general pop), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.77[1.55; 2.03]1,3302,337 -NAMoore (Pregabalin) (Mixed indications) (Controls exposed to LTG), 2025 10.510.01.0